• In late February 2026, U.S. Physical Therapy reported fourth-quarter 2025 revenue of US$202.73 million and net income of US$4.15 million, announced a 10‑year alliance that will fold a subsidiary’s ten clinics into a local hospital’s network by year-end 2026, approved a quarterly dividend increase to US$0.46 per share effective for April 10, 2026, and disclosed an upcoming CFO transition with Jason Curtis stepping in on an interim basis.
• Alongside these updates, management raised full‑year adjusted EBITDA guidance on the back of record clinic volumes and strong growth across core physical therapy and injury prevention services, signaling that cost discipline and new service lines are shaping how the company is responding to reimbursement pressures.
• Next, we’ll examine how the upgraded full-year EBITDA guidance and record clinic volumes influence U.S. Physical Therapy’s investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

U.S. Physical Therapy Investment Narrative Recap

To own U.S. Physical Therapy, you need to believe its clinic footprint and employer services can keep filling schedules even as reimbursement and labor pressures persist. The recent guidance hike suggests record volumes remain the key short term catalyst, while the biggest risk continues to be reimbursement and payer pressure, which this update does not materially change.

Among the latest announcements, the raised full year adjusted EBITDA guidance tied to record clinic volumes is most relevant. It reinforces the idea that cost control and higher visit counts are doing the heavy lifting for earnings, which matters if reimbursement pressure or staffing tightness later constrain pricing power.

Yet even with higher EBITDA guidance, investors should be aware that ongoing Medicare and commercial payer pressure could still...

U.S. Physical Therapy's narrative projects $918.4 million revenue and $52.5 million earnings by 2028. This requires 8.3% yearly revenue growth and a $17.9 million earnings increase from $34.6 million today.

Uncover how U.S. Physical Therapy's forecasts yield a $106.83 fair value, a 32% upside to its current price.

Exploring Other Perspectives

One Simply Wall St Community member values U.S. Physical Therapy at US$106.83 per share, reflecting a single, concentrated view. You can weigh this against the volume driven EBITDA catalyst described earlier and consider how reimbursement risk might affect future outcomes.

Explore another fair value estimate on U.S. Physical Therapy - why the stock might be worth just $106.83!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your U.S. Physical Therapy research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free U.S. Physical Therapy research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate U.S. Physical Therapy's overall financial health at a glance.

Curious About Other Options?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find 50 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.